Intravenous recombinant tissue plasminogen activator (tPA) remains the only specific pharmacological therapy for cerebral ischemia, but the narrow time window (within 4.5 h) of thrombolytic therapy and risk of hemorrhagic transformation limit its use.4, 5, 6. The gene discussed is PLAT; the disease is brain ischemia.